Literature DB >> 23953447

1H-13C NMR-based urine metabolic profiling in autism spectrum disorders.

Sylvie Mavel1, Lydie Nadal-Desbarats, Hélène Blasco, Frédérique Bonnet-Brilhault, Catherine Barthélémy, Frédéric Montigny, Pierre Sarda, Frédéric Laumonnier, Patrick Vourc'h, Christian R Andres, Patrick Emond.   

Abstract

Autism Spectrum Disorders (ASD) are a group of developmental disorders caused by environmental and genetic factors. Diagnosis is based on behavioral and developmental signs detected before 3 years of age with no reliable biological marker. The purpose of this study was to evaluate the potential use of a 2D NMR-based approach to express the global biochemical signature of autistic individuals compared to normal controls. This technique has greater spectral resolution than to 1D (1)H NMR spectroscopy, which is limited by overlapping signals. The urinary metabolic profiles of 30 autistic and 28 matched healthy children were obtained using a (1)H-(13)C NMR-based approach. The data acquired were processed by multivariate orthogonal partial least-squares discriminant analysis (OPLS-DA). Some discriminating metabolites were identified: β-alanine, glycine, taurine and succinate concentrations were significatively higher, and creatine and 3-methylhistidine concentrations were lower in autistic children than in controls. We also noted differences in several other metabolites that were unidentified but characterized by a cross peak correlation in (1)H-(13)C HSQC. Statistical models of (1)H and (1)H-(13)C analyses were compared and only 2D spectra allowed the characterization of statistically relevant changes [R(2)Y(cum)=0.78 and Q(2)(cum)=0.60] in the low abundance metabolites. This method has the potential to contribute to the diagnosis of neurodevelopment disorders but needs to be validated on larger cohorts and on other developmental disorders to define its specificity.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Autism spectrum disorders; HSQC NMR spectroscopy; Metabolomics; OPLS-DA; Urinary metabolites

Mesh:

Year:  2013        PMID: 23953447     DOI: 10.1016/j.talanta.2013.03.064

Source DB:  PubMed          Journal:  Talanta        ISSN: 0039-9140            Impact factor:   6.057


  26 in total

1.  The Brain-Gut-Microbiome Axis: What Role Does It Play in Autism Spectrum Disorder?

Authors:  Ruth Ann Luna; Tor C Savidge; Kent C Williams
Journal:  Curr Dev Disord Rep       Date:  2016-02-26

Review 2.  The phenolic interactome and gut microbiota: opportunities and challenges in developing applications for schizophrenia and autism.

Authors:  George E Jaskiw; Mark E Obrenovich; Curtis J Donskey
Journal:  Psychopharmacology (Berl)       Date:  2019-06-13       Impact factor: 4.530

3.  The Metabolic Disturbances of Motoneurons Exposed to Glutamate.

Authors:  Blandine Madji Hounoum; Hélène Blasco; Emmanuelle Coque; Patrick Vourc'h; Patrick Emond; Philippe Corcia; Christian R Andres; Cédric Raoul; Sylvie Mavel
Journal:  Mol Neurobiol       Date:  2018-02-12       Impact factor: 5.590

4.  Metabolic profiling in children with autism spectrum disorder with and without mental regression: preliminary results from a cross-sectional case-control study.

Authors:  O D Rangel-Huerta; A Gomez-Fernández; M J de la Torre-Aguilar; A Gil; J L Perez-Navero; K Flores-Rojas; P Martín-Borreguero; M Gil-Campos
Journal:  Metabolomics       Date:  2019-06-27       Impact factor: 4.290

5.  Curcumin and NCLX inhibitors share anti-tumoral mechanisms in microsatellite-instability-driven colorectal cancer.

Authors:  William Raoul; Thierry Lecomte; Maxime Guéguinou; Sajida Ibrahim; Jérôme Bourgeais; Alison Robert; Trayambak Pathak; Xuexin Zhang; David Crottès; Jacques Dupuy; David Ternant; Valérie Monbet; Roseline Guibon; Hector Flores-Romero; Antoine Lefèvre; Stéphanie Lerondel; Alain Le Pape; Jean-François Dumas; Philippe G Frank; Alban Girault; Romain Chautard; Françoise Guéraud; Ana J García-Sáez; Mehdi Ouaissi; Patrick Emond; Olivier Sire; Olivier Hérault; Gaëlle Fromont-Hankard; Christophe Vandier; David Tougeron; Mohamed Trebak
Journal:  Cell Mol Life Sci       Date:  2022-05-08       Impact factor: 9.261

6.  NMR-Based Metabolomics of Rat Hippocampus, Serum, and Urine in Two Models of Autism.

Authors:  B Toczylowska; E Zieminska; R Polowy; K H Olszynski; J W Lazarewicz
Journal:  Mol Neurobiol       Date:  2022-06-17       Impact factor: 5.682

7.  Plasma and Fecal Metabolite Profiles in Autism Spectrum Disorder.

Authors:  Brittany D Needham; Mark D Adame; Gloria Serena; Destanie R Rose; Gregory M Preston; Mary C Conrad; A Stewart Campbell; David H Donabedian; Alessio Fasano; Paul Ashwood; Sarkis K Mazmanian
Journal:  Biol Psychiatry       Date:  2020-10-10       Impact factor: 13.382

8.  Studying Autism Using Untargeted Metabolomics in Newborn Screening Samples.

Authors:  Julie Courraud; Madeleine Ernst; Susan Svane Laursen; David M Hougaard; Arieh S Cohen
Journal:  J Mol Neurosci       Date:  2021-01-30       Impact factor: 3.444

9.  Gene-Environment Interactions in Developmental Neurotoxicity: a Case Study of Synergy between Chlorpyrifos and CHD8 Knockout in Human BrainSpheres.

Authors:  Sergio Modafferi; Xiali Zhong; Andre Kleensang; Yohei Murata; Francesca Fagiani; David Pamies; Helena T Hogberg; Vittorio Calabrese; Herbert Lachman; Thomas Hartung; Lena Smirnova
Journal:  Environ Health Perspect       Date:  2021-07-14       Impact factor: 9.031

Review 10.  Profiles of urine and blood metabolomics in autism spectrum disorders.

Authors:  Narueporn Likhitweerawong; Chanisa Thonusin; Nonglak Boonchooduang; Orawan Louthrenoo; Intawat Nookaew; Nipon Chattipakorn; Siriporn C Chattipakorn
Journal:  Metab Brain Dis       Date:  2021-08-02       Impact factor: 3.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.